One of the most compelling long-term investment themes today is the transformation of global healthcare. While advances in medicine and biotechnology often make headlines, the real driver behind this trend is a profound demographic shift that is reshaping economies around the world.
The World Is Getting Older
People are living longer than ever before. According to the United Nations, by 2050, one in six people globally will be aged 65 or older, compared to one in 11 in 2019. In many developed countries, this trend is already well underway. Nearly 30% of Japan’s population is over the age of 65, while Italy has one of the oldest populations in Europe, with around 24% of its citizens aged 65 or older.
At the same time, fertility rates continue to decline. Global fertility rates have fallen from about five children per woman in the 1950s to roughly 2.3 today. In some countries, the decline is even more pronounced. South Korea, for example, currently has a fertility rate of about 0.8 children per woman, well below the 2.1 level generally considered necessary to maintain long-term population stability.
These demographic changes carry significant economic implications. As populations age, healthcare spending rises, demand for chronic disease management increases, and governments face growing pressure on healthcare and pension systems.
From Lifespan to Healthspan
Importantly, the healthcare industry is evolving beyond simply helping people live longer. Increasingly, the focus is shifting towards improving “healthspan”, the number of years people remain healthy, active and productive. This evolution is driving innovation across a wide range of healthcare-related industries, including biotechnology, diagnostics, preventative healthcare, medical technology and pharmaceutical development.
As a result, healthcare is no longer merely viewed as a defensive investment sector. It is increasingly becoming a source of innovation and growth.
The Rise of Obesity Treatments
One area attracting significant attention is obesity treatment. The World Health Organisation estimates that 2.5 billion adults worldwide are overweight, while more than 890 million adults are classified as obese. This means that around 43% of the global adult population is overweight.
Recent breakthroughs in GLP-1 medications, originally developed to treat diabetes, have transformed the conversation around obesity management. These treatments have generated widespread public awareness and have the potential to significantly improve long-term health outcomes by addressing one of the world’s most significant healthcare challenges.
The economic impact is already substantial. Global spending on anti-obesity medicines exceeded USD 30 billion in 2024, representing a tenfold increase compared to 2020. Industry forecasts suggest the market could continue expanding rapidly over the coming decade. While markets often focus on the short-term excitement surrounding new innovations, investors should remain focused on the longer-term structural changes these developments may create within healthcare systems globally.
Healthcare Versus Biotechnology
From an investment perspective, it is important to distinguish between healthcare and biotechnology. Healthcare as a sector includes a broad range of businesses such as pharmaceutical companies, medical equipment manufacturers, healthcare service providers and diagnostics firms. Historically, diversified healthcare investments have delivered attractive long-term returns while also providing some defensive characteristics during periods of economic uncertainty.
Biotechnology, however, tends to be significantly more volatile. Share prices can often move rapidly based on clinical trial results, regulatory approvals or scientific breakthroughs. While the growth potential can be substantial, so too can the risks. For this reason, investors should generally avoid trying to identify the next breakthrough biotechnology company in isolation. Instead, a diversified approach across the broader healthcare ecosystem may provide more balanced exposure to both innovation and long-term growth opportunities.
Look Ahead
Healthcare is often viewed as a defensive component of an investment portfolio. However, the sector is increasingly becoming one of the most important innovation stories of the next decade.
Ageing populations, declining birth rates, advances in biotechnology, improved diagnostics, preventative medicine and new treatment options are creating powerful structural tailwinds that are likely to shape investment markets for many years to come. For long-term investors, healthcare represents more than a short-term trend. It is a global transformation driven by demographics, technology and innovation and one that may offer significant opportunities as the world continues to evolve.
For further insight into healthcare and biotechnology trends and their market implications, read the full analysis on Moneyweb, featuring commentary from director Sean Kelly.
